174722-30-6
174722-30-6 structure
- Name: Keliximab
- Chemical Name: Keliximab
- CAS Number: 174722-30-6
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
- Create Date: 2018-07-18 13:22:41
- Modify Date: 2024-02-05 11:20:04
-
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research[1][2].
| Name | Keliximab |
|---|
| Description | Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Keliximab 与可溶性 CD4 结合的 Kd 值为 1.0 nM[2]。 Keliximab (0.01-10 μg/mL；30 分钟) 剂量依赖性地结合 CD4+ 胸腺瘤细胞系 SupT1，ED50 为 0.2 μg/mL[1]。 Keliximab (0-1000ng/mL) 在原发性人浆母细胞淋巴瘤 (PBLs) 中阻断 T 细胞增殖和 IL-2 产生，IC50 为 10-30 ng/mL[1]。 Keliximab (1-1000 ng/mL；5 分钟) 剂量依赖性地介导细胞粘附，ED50 为 20 ng/mL[1]。 |
| In Vivo | Keliximab (5-125 mg/kg；静脉注射，1 次) 减少 CD4+ T 细胞[1]。 Animal Model: Transgenic mice bearing human CD4 molecules on their T cells[1] Dosage: 5-125 mg/kg Administration: Intravenous injection, 5-125 mg/kg, once Result: Dose-dependently down-modulated CD4 and rapidly declined the number of circulating CD4+ T cells compared with clenoliximab. |
| References |
| No Any Chemical & Physical Properties |